CPDC has launched Cadena Research, a new preclinical contract research organisation (CRO) offering specialized support for early-stage drug development in the radiopharmaceutical sector.
Cadena Research bridges a gap in the rapidly expanding radiopharmaceutical industry by delivering preclinical development support to innovators worldwide. The organisation provides services including in vitro and in vivo research and development, screening, lead optimisation, toxicology, dosimetry, imaging, and advanced radiochemistry capabilities. In addition, Cadena Research offers GLP capabilities for IND-enabling studies. Clients benefit from strategic advisory services offered by a team of experienced radiopharmaceutical professionals. Every project is managed from inception through to completion by a dedicated project manager, ensuring seamless communication and timely delivery.
Cadena Research is led by Martin Poirier, vice president of contract research.
“Our goal at Cadena Research is to empower the next generation of radiopharmaceutical breakthroughs, and the success of our clients is our top priority,” Poirier said.
“We provide tailored preclinical support and expert guidance to help radiopharmaceutical innovators move efficiently from discovery to clinical translation, ultimately bringing their products to market with confidence. The new CRO service represents a significant step forward to continue accelerating the development of innovative treatments and contributing to the growth of the global radiopharmaceutical sector.”
“As the radiopharmaceutical industry experiences unprecedented growth, the need for specialized, agile preclinical support has never been greater.”, said Owen Roberts, CEO of CPDC.
“The launch of Cadena Research builds upon our proven track record of creating successful global ventures that advance the radiopharmaceutical field. Following the achievements of Fusion Pharmaceuticals and AtomVie Global Radiopharma, we are confident that Cadena Research will continue this legacy by providing researchers with the specialized preclinical support they need to move their innovations from concept to clinic more efficiently.”
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
